DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Aniracetam (HB0116)
Description:Nootrophic AMPA receptor positive allosteric modulator
Purity:>98%
-
-
-
CIQ (HB0197)
Description:GluN2C / GluN2D subunit selective NMDA receptor positive allosteric modulator
Purity:>98%
-
Cyclothiazide (HB0221)
Description:AMPA receptor positive allosteric modulator. Inhibits AMPAR desensitization.
Purity:>98%
-
-
-
-
UBP709 (HB9204)
Description:NMDAR pan-PAM that potentiates all GluN2 subunits. Enhances LTD and decreases LTP.
Purity:>98%
-
UBP714 ammonium salt (HB8161)
Description:NMDAR PAM which potentiates GluN2A and GluN2B with minimal effects on 2C and 2D.
Purity:>98%
